Plasmodium falciparum Raw Sequence Reads of the first whole-genome sequencing of Togo clinical isolates

In early investigations in Togo, clinical and parasitological therapeutic failure tests of artemether-lumefarine (AL)(3%) and artesunate-amodiaquine (ASAQ) for being 3% and 3.8%, respectively, have been observed (Togo PNLP, 2012-2013) and drew the entire country's attention to an eventual resistance to artemisinins. However, in a recent study, therapeutic efficacy of AL and ASAQ was shown high, without delay in the clearance of mutant parasites (Dorkenoo et al., 2016). More so, Plasmodium falciparum surface-exposed protein antigens are targets of host immune responses and, repeated exposures to the parasite in endemic areas induce a slow and gradual development of immunity to clinical malaria, which is usually evidenced as a decline in the prevalence of clinical episodes. Hence, biological insights on both immunity-related antigens and drug resistance genes for effective interventions to sustain and drive forward the struggle against malaria parasite in Togo, is a research priority.